Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Zhongguo Yufang Shouyi Xuebao / Chinese Journal of Preventive Veterinary Medicine ; 44(10):1059-1065, 2022.
Article in Chinese | CAB Abstracts | ID: covidwho-2327435

ABSTRACT

Bovine rhinitis virus (BRV) is an important pathogen responsible for the bovine respiratory disease complex (BRDC) and can be divided into two genotypes (BRAV and BRBV). To establish a duplex quantitative real-time RT-PCR assay for simultaneous detection of BRAV and BRBV, specific primers and TaqMan probes targeting the 5'NTR of BRAV and 3'NTR of BRBV were designed. A duplex quantitative real- time RT- PCR assay for simultaneous detecting BRAV and BRBV was preliminarily established by optimizing reaction conditions for each step. The assay specifically detects BRAV and BRBV, and no crossreaction with other common bovine respiratory pathogens, including IDV, BCoV, BVDV-1, BRSV, BPIV-3, BAdV-3, mycoplasma bovis, Pasteurella multocida, Mannheimia haemolytica, Escherichia coli, and Salmonella, was observed. In addition, the sensitivity test showed that the detection limits of this assay were 3.2x101 copies/L for both BRAV and BRBV plasmid standards. Besides, the repeatability test showed that the variation coefficients of this assay were less than 0.05 from both lot-to-lot and intra-lot. These results showed that the assay has high specificity, extreme sensitivity, and good repeatability. Moreover, a total of 43 nasal swabs of BRDC cattle were tested by our assay and four other quantitative real-time RT-PCR assays, including 3 BRAV assays and 4 BRBV assays. The results showed that the detection rates of our assay were 32.56%(14/43) for BRAV and 30.23%(13/43) for BRBV, and the detection rates of other quantitative real-time RT-PCR assays were 0(0/43), 2.33%(1/43), 23.26%(10/43) for BRAV and 27.91% (12/43), 27.91%(12/43), 27.91%(12/43), 27.91%(12/43) for BRBV, indicating that our assay has a more substantial detection capability than other assays. This study firstly established a duplex quantitative real-time RT-PCR assay for simultaneous detection of BRAV and BRBV, and the assay exhibited high specificity, sensitivity, and stability. Moreover, the study firstly confirmed the existence of BRAV in China, contributing to the prevention and control of BRDC.

2.
Front Pharmacol ; 13: 832750, 2022.
Article in English | MEDLINE | ID: covidwho-2224846

ABSTRACT

Inflammation is an essential immune response of the host against infections but is often over-activated, leading to a variety of disorders. Autophagy, a conserved degradation pathway, also protects cells by capturing intracellular pathogens that enter the cell and transporting them to the lysosome for clearance. Dysfunctional autophagy is often associated with uncontrolled inflammatory responses during infection. In recent years, more and more research has focused on the crosstalk between autophagy and inflammation. In this paper, we review the latest research advances in this field, hoping to gain insight into the mechanisms by which the body balances autophagy and inflammation in infections and how this mechanism can be used to fight infections better.

3.
Front Pharmacol ; 13: 936925, 2022.
Article in English | MEDLINE | ID: covidwho-2022836

ABSTRACT

Background: Coronavirus disease 2019 (COVID-19) was declared a global pandemic in March 2020 by the World Health Organization (WHO). As of July 2, 2022, COVID-19 has caused more than 545 million infections and 6.3 million deaths worldwide, posing a significant threat to human health. Currently, there is still a lack of effective prevention and control strategies for the variation and transmission of SARS-CoV-2. Traditional Chinese medicine (TCM), which has a unique theoretical system, has treated various conditions for thousands of years. Importantly, recent studies have revealed that TCM contributed significantly to COVID-19. SanHanHuaShi (SHHS) granules, a Chinese herbal medicine, which has been included in Protocol for the Diagnosis and Treatment of Novel Coronavirus Disease 2019 (6th to 9th editions) issued by the National Health Commission of China and used to prevent and treat COVID-19 disease. A previous retrospective cohort study showed that SHHS could significantly reduce the severity of mild and moderate COVID-19. However, there is an absence of high-quality randomized controlled clinical studies to confirm the clinical effectiveness of SHHS. Therefore, a clinical study protocol and a statistical analysis plan were designed to investigate the efficacy and safety of SHHS for the prevention and treatment of COVID-19. This study will increase the integrity and data transparency of the clinical research process, which is of great significance for improving the practical application of SHHS granules in the future. Methods and analysis: The study was designed as a 7-day, randomized, parallel controlled, open-label, noninferiority clinical trial of positive drugs. A total of 240 patients with mild and moderate COVID-19 will be enrolled and randomly assigned to receive SanHanHuaShi granules or LianHuaQingWen granules treatment in a 1:1 ratio. Disease classification, vital signs, SARS-CoV-2 nucleic acid testing, symptoms, medications, adverse events, and safety evaluations will be recorded at each visit. The primary outcome will be the clinical symptom recovery rate. Secondary outcomes will include the recovery time of clinical symptoms, negative conversion time of SARS-CoV-2 nucleic acid test negative conversion rate, hospitalization time, antipyretic time, rate of conversion to severe patients, and time and rate of single symptom recovery. Adverse incidents and safety assessments will be documented. All data will be analyzed using a predetermined statistical analysis plan, including our method for imputation of missing data, primary and secondary outcome analyses, and safety outcomes. Discussion: The results of this study will provide robust evidence to confirm the effectiveness and safety of SHHS in the treatment of COVID-19. Clinical Trial Registration: http://www.chictr.org.cn. Trial number: ChiCTR2200058080. Registered on 29 March 2022.

4.
PLoS One ; 17(7): e0267160, 2022.
Article in English | MEDLINE | ID: covidwho-1968856

ABSTRACT

Policymakers around the world are enforcing mobility restriction policies such as lockdowns, facemask requirements and social distancing to curb the spread of Covid-19. While these policies are effective in preventing the spread of virus, the economic implications are not well understood. We contribute to the literature by examining the impact of these policies on the offline retail sector. Specifically, we measure the effects of these policies on the daily number of shoppers passing by, which we refer to as 'footfall', along major shopping streets in Netherlands. We rely on unique proprietary Wifi data to accurately measure footfall. Our findings imply that all these policies attribute to a non-trivial reduction in footfall levels along shopping streets. While lockdowns led to a 50% reduction in footfall along major shopping streets, shopping streets faced with facemask regulations also experience a 25% drop in human traffic. A reduction in footfall translates into a substantial reduction in retail income of between 12% and 25%.


Subject(s)
COVID-19 , COVID-19/epidemiology , COVID-19/prevention & control , Communicable Disease Control , Humans , Masks , Physical Distancing , Public Policy
5.
Gut ; 71(2): 238-253, 2022 02.
Article in English | MEDLINE | ID: covidwho-1622066

ABSTRACT

OBJECTIVE: Helicobacter pylori infection is mostly a family-based infectious disease. To facilitate its prevention and management, a national consensus meeting was held to review current evidence and propose strategies for population-wide and family-based H. pylori infection control and management to reduce the related disease burden. METHODS: Fifty-seven experts from 41 major universities and institutions in 20 provinces/regions of mainland China were invited to review evidence and modify statements using Delphi process and grading of recommendations assessment, development and evaluation system. The consensus level was defined as ≥80% for agreement on the proposed statements. RESULTS: Experts discussed and modified the original 23 statements on family-based H. pylori infection transmission, control and management, and reached consensus on 16 statements. The final report consists of three parts: (1) H. pylori infection and transmission among family members, (2) prevention and management of H. pylori infection in children and elderly people within households, and (3) strategies for prevention and management of H. pylori infection for family members. In addition to the 'test-and-treat' and 'screen-and-treat' strategies, this consensus also introduced a novel third 'family-based H. pylori infection control and management' strategy to prevent its intrafamilial transmission and development of related diseases. CONCLUSION: H. pylori is transmissible from person to person, and among family members. A family-based H. pylori prevention and eradication strategy would be a suitable approach to prevent its intra-familial transmission and related diseases. The notion and practice would be beneficial not only for Chinese residents but also valuable as a reference for other highly infected areas.


Subject(s)
Family Health , Helicobacter Infections/prevention & control , Helicobacter pylori , Infection Control/organization & administration , Adolescent , Adult , Aged , Child , Child, Preschool , China , Consensus , Delphi Technique , Helicobacter Infections/diagnosis , Helicobacter Infections/transmission , Humans , Infant , Middle Aged , Young Adult
6.
Appl Soft Comput ; 111: 107683, 2021 Nov.
Article in English | MEDLINE | ID: covidwho-1454011

ABSTRACT

In 2020, a novel coronavirus disease became a global problem. The disease was called COVID-19, as the first patient was diagnosed in December 2019. The disease spread around the world quickly due to its powerful viral ability. To date, the spread of COVID-19 has been relatively mild in China due to timely control measures. However, in other countries, the pandemic remains severe, and COVID-19 protection and control policies are urgently needed, which has motivated this research. Since the outbreak of the pandemic, many researchers have hoped to identify the mechanism of COVID-19 transmission and predict its spread by using machine learning (ML) methods to supply meaningful reference information to decision-makers in various countries. Since the historical data of COVID-19 is time series data, most researchers have adopted recurrent neural networks (RNNs), which can capture time information, for this problem. However, even with a state-of-the-art RNN, it is still difficult to perfectly capture the temporal information and nonlinear characteristics from the historical data of COVID-19. Therefore, in this study, we develop a novel dendritic neural regression (DNR) method to improve prediction performance. In the DNR, the multiplication operator is used to capture the nonlinear relationships between input feature signals in the dendrite layer. Considering the complex and large landscape of DNR's weight space, a new scale-free state-of-matter search (SFSMS) algorithm is proposed to optimize the DNR, which combines the state-of-matter search algorithm with a scale-free local search. The SFSMS achieves a better global search ability and thus can effectively reduce the possibility of falling into local minima. In addition, according to Takens's theorem, phase space reconstruction techniques are used to discover the information hidden in the high-dimensional space of COVID-19 data, which further improves the precision of prediction. The experimental results suggest that the proposed method is more competitive in solving this problem than other prevailing methods.

7.
Mil Med Res ; 8(1): 13, 2021 02 16.
Article in English | MEDLINE | ID: covidwho-1088620

ABSTRACT

BACKGROUND: Until January 18, 2021, coronavirus disease-2019 (COVID-19) has infected more than 93 million individuals and has caused a certain degree of panic. Viral pneumonia caused by common viruses such as respiratory syncytial virus, rhinovirus, human metapneumovirus, human bocavirus, and parainfluenza viruses have been more common in children. However, the incidence of COVID-19 in children was significantly lower than that in adults. The purpose of this study was to describe the clinical manifestations, treatment and outcomes of COVID-19 in children compared with those of other sources of viral pneumonia diagnosed during the COVID-19 outbreak. METHODS: Children with COVID-19 and viral pneumonia admitted to 20 hospitals were enrolled in this retrospective multi-center cohort study. A total of 64 children with COVID-19 were defined as the COVID-19 cohort, of which 40 children who developed pneumonia were defined as the COVID-19 pneumonia cohort. Another 284 children with pneumonia caused by other viruses were defined as the viral pneumonia cohort. The epidemiologic, clinical, and laboratory findings were compared by Kolmogorov-Smirnov test, t-test, Mann-Whitney U test and Contingency table method. Drug usage, immunotherapy, blood transfusion, and need for oxygen support were collected as the treatment indexes. Mortality, intensive care needs and symptomatic duration were collected as the outcome indicators. RESULTS: Compared with the viral pneumonia cohort, children in the COVID-19 cohort were mostly exposed to family members confirmed to have COVID-19 (53/64 vs. 23/284), were of older median age (6.3 vs. 3.2 years), and had a higher proportion of ground-glass opacity (GGO) on computed tomography (18/40 vs. 0/38, P < 0.001). Children in the COVID-19 pneumonia cohort had a lower proportion of severe cases (1/40 vs. 38/284, P = 0.048), and lower cases with high fever (3/40 vs. 167/284, P < 0.001), requiring intensive care (1/40 vs. 32/284, P < 0.047) and with shorter symptomatic duration (median 5 vs. 8 d, P < 0.001). The proportion of cases with evaluated inflammatory indicators, biochemical indicators related to organ or tissue damage, D-dimer and secondary bacterial infection were lower in the COVID-19 pneumonia cohort than those in the viral pneumonia cohort (P < 0.05). No statistical differences were found in the duration of positive PCR results from pharyngeal swabs in 25 children with COVID-19 who received antiviral drugs (lopinavir-ritonavir, ribavirin, and arbidol) as compared with duration in 39 children without antiviral therapy [median 10 vs. 9 d, P = 0.885]. CONCLUSION: The symptoms and severity of COVID-19 pneumonia in children were no more severe than those in children with other viral pneumonia. Lopinavir-ritonavir, ribavirin and arbidol do not shorten the duration of positive PCR results from pharyngeal swabs in children with COVID-19. During the COVID-19 outbreak, attention also must be given to children with infection by other pathogens infection.


Subject(s)
COVID-19/epidemiology , Severe Acute Respiratory Syndrome/epidemiology , Adolescent , COVID-19/physiopathology , COVID-19/therapy , Child , Child, Preschool , China/epidemiology , Female , Humans , Infant , Male , Pandemics , Retrospective Studies , SARS-CoV-2 , Severe Acute Respiratory Syndrome/physiopathology , Severe Acute Respiratory Syndrome/therapy , Severity of Illness Index
8.
Zhongguo Yufang Shouyi Xuebao / Chinese Journal of Preventive Veterinary Medicine ; 42(9):918-922, 2020.
Article in Chinese | CAB Abstracts | ID: covidwho-890449

ABSTRACT

In order to establish a specific and sensitive TaqMan- based real- time RT- PCR assay for detecting Bovine coronavirus (BCoV) and its RNA in calf diarrhea clinical samples, a pair of primers and one probe targeting to nsp10 polymerase gene of BcoV were designed. After optimizing the reaction conditions, a TaqMan-based real-time RT-PCR assay was successfully established. The assay showed a good linear relationship within the range of 3.36 x 101 copies/L- 3.36 x 109 copies/L, with a correlation coefficient of R2=0.9996, and the amplification efficiency was 109%. This assay only specifically detected BCoV with a detection limit of 33.6 copies/L, whereas no other common unrelated pathogens could be detecteed. Compared to other methods, this assay has a slightly higher sensitivity;both the intra- and the inter- assay coefficients of variation were less than 5%, indicating its good reproducibility. The detection rate of BCoV for diarrhea samples was higher than that of a previously reported TaqManbased real-time RT-PCR assay. Moreover, 153 diarrhea samples of dairy calves were collected from Xinjiang and Liaoning regions, 71.23% of the samples were detected as BCoV positive, and the farm positive rate was 100%, suggesting that BCoV infection in cattle is common in these regions. In conclusion, a real-time RT-PCR assay targeting the BCoV polymerase gene was successfully established for the first time. This assay has high sensitivity, specificity, and reproducibility, which would contribute to the detection and epidemiological investigation of BCoV.

9.
Arch Virol ; 165(12): 3011-3015, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-833995

ABSTRACT

The hemagglutinin-esterase (HE) protein of betacoronavirus lineage A is a secondary receptor in the infection process and is involved in the emergence of new betacoronavirus genotypes with altered host specificity and tissue tropism. We previously reported a novel recombinant bovine coronavirus (BCoV) strain that was circulating in dairy cattle in China, but this virus was not successfully isolated, and the genetic characteristics of BCoV are still largely unknown. In this study, 20 diarrheic faecal samples were collected from a farm in Liaoning province that had an outbreak of calf diarrhea (≤ 3 months of age) in November 2018, and all of the samples tested positive for BCoV by RT-PCR. In addition, a BCoV strain with a recombinant HE (designated as SWUN/A1/2018) and another BCoV strain with a recombinant HE containing an insertion (designated as SWUN/A10/2018) were successfully isolated in cell culture (TCID50: 104.25/mL and 104.73/mL, respectively). Unexpectedly, we identified the emergence of a novel BCoV variant characterized by a 12-nt bovine gene insertion in the receptor-binding domain in a natural recombinant HE gene, suggesting a novel evolutionary pattern in BCoV.


Subject(s)
Cattle Diseases/epidemiology , Coronavirus Infections/veterinary , Coronavirus, Bovine/genetics , Diarrhea/veterinary , Hemagglutinins, Viral/genetics , RNA, Viral/genetics , Viral Fusion Proteins/genetics , Animals , Cattle , Cattle Diseases/pathology , Cattle Diseases/virology , China/epidemiology , Coronavirus Infections/epidemiology , Coronavirus Infections/pathology , Coronavirus Infections/virology , Coronavirus, Bovine/classification , Coronavirus, Bovine/isolation & purification , Diarrhea/epidemiology , Diarrhea/pathology , Diarrhea/virology , Evolution, Molecular , Feces/virology , Gene Expression , Genotype , Models, Molecular , Mutagenesis, Insertional , Phylogeny , Protein Structure, Secondary , Reverse Transcriptase Polymerase Chain Reaction , Sequence Analysis, DNA
SELECTION OF CITATIONS
SEARCH DETAIL